Value Based Pricing & Pay for Performance Agreements with New Medicines - How big data is filling the value gap & value mismatch

Access & reimbursement of medicines has started a paradigm shoft from “volume to value”. Essential to this is clinical data with capabilities for collection and analysis with shared platforms which is becoming ever important to payers and reimbursement authorities.

However the narrative is yet to be aligned, both across varying nations and the nature of the data and platforms required to demonstrate value and indeed aspirational prices for medicines.

This presentation by a former payer brings to life how payers are using the concept of co-creation of data sets to demonstrate product value, access and reimbursment that will pave the way for future pricing and reimbursment models.Indeed scalability of such platforms has been highglighted as key for payers & pharma manufacturers.

  • How are payers addressing global health economy and innovative medicines medicines?
  • Value based agreements nomenclature and data driven requirements of HTA/national payer bodies assist with pricing, access & reimbursement
  • The Cancer Drugs Fund - conditional reimbursement models with RWE platforms paying for performance in oncology
  • RWE Outcomes Based Contracting - real examples of pay for performance reimbursement for cancer medicines across EU & US
  • Can we afford a cure ? Sustainable drug leasing models and data platform models for regenerative cell therapies & gene therapies

About the speaker
Omar Ali

Qualified with a hospital pharmacy background, Omar has been working as the Formulary Advisor for Surrey & Sussex Healthcare NHS Trust for over 15 years, sitting on the regional Joint Drugs & Therapeutics Committee as well as the CCG/Commissioning Prescribing Clinical Network.
Omar has been a visiting Lecturer at UCLH Pharmacy Programme and was both Lecturer & Examiner on the Independent Prescribing V300 Course at the University of Surrey and has over 30 publications to date. He has been appointed as Visiting Lecturer on Value Based Pricing & Innovative Contracting at the University of Portsmouth, is an Editorial Content Adviser to Guidelines, and has recently been invited to the position of Associate Editor to the Canadian Journal of Population Therapeutics & Clinical Pharmacology.
Omar has served a position on the External Reference Group on Cost Impact Modelling for NICE for 6 years and was subsequently appointed Panel Member for the newly formed Adoption & Impact Program Reference for NICE. He advises foreign investors (US Embassy) on ‘Value Based Assessments (hosted by the UK Department of Trade & Industry) and recently delivered a Healthcare NHS Reform program to over 40 Healthcare Insurance Provider delegates visiting from the US.
Last year he was invited to address the Italian Healthcare Senate [Senato della Repubblica] on Pharmaco-economic Evaluation & Sustainability Models of Healthcare and featured at the Westminster Health Forum Keynote Seminars [chaired by Lord Howe, All Party Parliamentary Group on Pharmacy] on the Future for Pharmacy Commissioning, Organisation & Delivery.
At this current time he has embarked on a PhD with his doctorate thesis entitled “Value Based Pricing & Outcomes Based, Innovative Contracting of New Medicines”.

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more